LIFEUSD does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2021-09-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
No Form 8-K filings for this ticker
CUSIP
002120103
FAQ
Who are the top institutional investors holding ATYR PHARMA INC (LIFEUSD)?
Major stakeholders currently include Polaris Venture Management Co. V, L.L.C. ($1.2M). Based on the latest 13F filings, there are a total of 1 tracked investment funds and institutions maintaining positions in LIFEUSD.
What is the overall institutional sentiment toward LIFEUSD recently?
Institutional sentiment appears Neutral. During the most recent reporting quarter, the stock experienced no significant net capital flow from tracked managers.
Which institutions have been selling or reducing their LIFEUSD positions?
In the latest period, no tracked funds trimmed or exited their positions in LIFEUSD.
Are there any notable investors adding LIFEUSD to their portfolios?
No tracked institutions opened new positions or added to their existing holdings in LIFEUSD during the last reporting period.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter